Singular Genomics (OMIC): Company Cash Volume

OMIC (singulargenomics.com) - company brandmark

The cash position of Singular Genomics Systems (OMIC) allows for the control of real liquidity, with the value of 0.11 expressing the metric level. Equipment sales are moderately cyclical due to a dependence on R&D budgets. Singular Genomics Systems (OMIC) is implementing fast analysis tools based on G4 to capture market share. However, the search for strategic alternatives and weak demand for systems keep financial results at minimal levels.

OMIC - Singular Genomics Systems Inc Company Cash on Hand over the range 07/04/2022 - 03/01/2025

Financial and market metric breakdowns for Singular Genomics Systems, Inc. (OMIC)

- stock value and consensus price forecast:
Product sample of Singular Genomics

For Singular Genomics Systems (OMIC), liquidity reserves determine the ability to maintain technological leadership in sequencing. This metric aggregates the volume of cash and equivalents available for the immediate coverage of operating expenses. By analyzing cash capital dynamics, investors assess the resilience of reserves against inflationary depreciation. This resource is critical for protecting patent optics and ensuring the supply of consumable reagents. A stable funding level confirms the business's financial autonomy.

Competitors of Singular Genomics Systems (OMIC)

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash Funds Rocket Pharmaceuticals|Company Cash on Hand 4DMT (FDMT)|Company Cash Volume LXEO|Company Liquid Assets Korro Bio Inc.|Company Cash Volume EDIT (Editas Medicine Inc)|SLN: Company Cash and Cash Equivalents|PRQR - Company Cash Funds|Company Liquid Assets codexis.com CDXS|SGMO: Company Cash Volume|Nautilus Biotechnology (NAUT) - Company Cash Volume|Company Cash Funds Metagenomi, Inc|precisionbiosciences.com (DTIL) - Company Liquid Assets|Company Cash Funds Generation Bio Co. (GBIO)|Company Liquid Assets Boundless Bio, Inc.|Company Cash Funds Exicure, Inc. XCUR|IMNN: Company Cash and Cash Equivalents|PHIO - Company Cash Funds|Company Liquid Assets Mustang Bio MBIO|RNAZ: Company Cash Volume|Company Cash Position Bionano Genomics Inc. BNGO|APDN (Applied DNA Corp) - Company Cash Volume|bluebirdbio.com (BLUE) - Company Liquid Assets|Company Cash Volume IPA|Company Cash Volume Omega (OMGA)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume